<DOC>
	<DOCNO>NCT00337168</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine clofarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well give cytarabine together clofarabine work treat patient relapsed refractory acute lymphoblastic leukemia .</brief_summary>
	<brief_title>S0530 Cytarabine Clofarabine Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Primary objective : - Determine whether complete remission rate adult patient relapse refractory acute lymphoblastic leukemia ( ALL ) sufficiently high treatment cytarabine clofarabine warrant investigation . Secondary objective : - Estimate frequency severity toxicity associate dose schedule cytarabine clofarabine . - Investigate , preliminarily , prognostic effect cytogenetic feature response treatment patient . Other objective ( fund allows ) : - Investigate , preliminarily , prognostic effect laboratory correlate ( expression nucleoside transporter , expression pertinent gene tissue microarray ) FISH feature response treatment patient OUTLINE : This open-label , multicenter study . - Induction therapy ( 1 2 course ) : Patients receive induction therapy comprise clofarabine IV 1 hour follow 4 hour later cytarabine IV 2 hour day 1-5 ( course 1 ) . Patients achieve response ( 5-25 % blast bone marrow ≥ 50 % reduction blast initial bone marrow aspirate ) receive 1 course induction therapy begin later day 45 . Patients achieve complete remission ( &lt; 5 % blast bone marrow ) 1 2 course induction therapy may proceed consolidation therapy . - Consolidation therapy ( 1 course ) : Beginning within 60 day first day last induction therapy , patient may receive consolidation therapy comprise clofarabine IV 1 hour follow 4 hour later cytarabine IV 2 hour day 1-4 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior morphologic diagnosis acute lymphoblastic leukemia ( ALL ) No M0 , mixed lineage , L3 ( Burkitt 's ) ALL Refractory standard induction regimen OR relapse successful prior induction therapy Standard induction regimen define program treatment include vincristine prednisone highdose cytarabine/mitoxantrone Any number induction remission allow Must evidence ALL bone marrow peripheral blood Immunophenotyping blood bone marrow lymphoblasts must perform determine lineage ( B cell , T cell , mixed B/T cell ) No extramedullary disease absence bone marrow blood involvement Coexpression myeloid antigen ( CD13 CD33 ) allow Patients Philadelphia chromosomepositive ( Ph+ ) ALL bcr/ablpositive ALL previously eligible imatinib mesylate treatment must receive imatinib mesylate either alone combination chemotherapy ALL must either fail treatment unable tolerate treatment No CNS involvement determine lumbar puncture ( previous CNS history clinical sign symptom CNS ) clinical exam ( previous history signs/symptoms ) Must register SWOGS9910 SWOG9007 PATIENT CHARACTERISTICS : Zubrod performance status 02 Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Bilirubin ≤ 1.5 time ULN No psychiatric disorder would interfere study compliance No uncontrolled systemic fungal , bacterial , viral , infection No severe concurrent disease No serious poorly control medical condition would preclude study participation No history serious organ dysfunction disease involve heart , kidney , liver , organ system would preclude study participation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexisting motor sensory neuropathy ≥ grade 2 No prior malignancy , except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer complete remission Any prior cancer patient disease free ≥ 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior clofarabine More 2 week since prior chemotherapy , major surgery , investigational agent More 6 week since prior monoclonal antibody Prior allogeneic autologous bone marrow transplant allow provide follow criterion meet : More 90 day since transplant No acute graftversushost disease ( GVHD ) ≥ grade 2 OR moderate severe limit chronic GVHD OR extensive chronic GVHD severity Prior maintenance therapy steroid , vincristine , and/or antimetabolite agent , , limit , mercaptopurine , thioguanine , methotrexate allow Concurrent hydroxyurea allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
</DOC>